The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review

The role of N-acetylcysteine (NAC) in the treatment of chronic bronchitis is unclear. Since a number of studies have been published on this topic, a systematic review of published studies seems justified. A systematic search (Medline, Embase, Cochrane Library, bibliographies, no language restriction) for published randomized trials comparing oral NAC with placebo in patients with chronic bronchitis was performed. Dichotomous data on prevention of exacerbation, improvement of symptoms and adverse effects were extracted from original reports. The relative benefit and number-needed-to-treat were calculated for both individual trials and combined data. Thirty-nine trials were retrieved; eleven (2,011 analysed patients), published 1976-1994, were regarded as relevant and valid according to preset criteria. In nine studies, 351 of 723 (48.5%) patients receiving NAC had no exacerbation compared with 229 of 733 (31.2%) patients receiving placebo (relative benefit 1.56 (95% confidence interval (CI) 1.37-1.77), number-needed-to-treat 5.8 (95% CI 4.5-8.1). There was no evidence of any effect of study period (12-24 weeks) or cumulative dose of NAC on efficacy. In five trials, 286 of 466 (61.4%) patients receiving NAC reported improvement of their symptoms compared with 160 of 462 (34.6%) patients receiving placebo (relative benefit 1.78 (95% CI 1.54-2.05), number-needed-to-treat 3.7 (95% CI 3.0-4.9)). With NAC, 68 of 666 (10.2%) patients reported gastrointestinal adverse effects compared with 73 of 671 (10.9%) taking placebo. With NAC, 79 of 1,207 (6.5%) patients withdrew from the study due to adverse effects, compared with 87 of 1,234 (7.1%) receiving placebo. In conclusion, with treatment periods of approximately 12-24 weeks, oral N-acetylcysteine reduces the risk of exacerbations and improves symptoms in patients with chronic bronchitis compared with placebo, without increasing the risk of adverse effects. Whether this benefit is sufficient to justify the routine and long-term use of N-acetylcysteine in all patients with chronic bronchitis should be addressed in further studies and cost-effectiveness analyses.

This article has been cited by other articles:

				P. Albert and P. M. A. Calverley Drugs (including oxygen) in severe COPD Eur. Respir. J., May 1, 2008; 31(5): 1114 - 1124. [Abstract] [Full Text] [PDF]

				I Sabroe, L C Parker, P M A Calverley, S K Dower, and M K B Whyte Pathological networking: a new approach to understanding COPD Postgrad. Med. J., May 1, 2008; 84(991): 259 - 264. [Abstract] [Full Text] [PDF]

				R. Siden and C. E. Johnson Stability of a flavored formulation of acetylcysteine for oral administration Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 558 - 561. [Abstract] [Full Text] [PDF]

				W. C. Bailey and D. P. Tashkin Pharmacologic Therapy: Novel Approaches for Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 543 - 548. [Abstract] [Full Text] [PDF]

				I. Sabroe, L. C Parker, P. M A Calverley, S. K Dower, and M. K B Whyte Pathological networking: a new approach to understanding COPD Thorax, August 1, 2007; 62(8): 733 - 738. [Abstract] [Full Text] [PDF]

				I. Rahman and I. M. Adcock Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J., July 1, 2006; 28(1): 219 - 242. [Abstract] [Full Text] [PDF]

				S Scott, P Walker, and P M A Calverley COPD exacerbations {middle dot} 4: Prevention Thorax, May 1, 2006; 61(5): 440 - 447. [Abstract] [Full Text] [PDF]

				S. S. Braman Chronic Cough Due to Chronic Bronchitis: ACCP Evidence-Based Clinical Practice Guidelines Chest, January 1, 2006; 129(1_suppl): 104S - 115S. [Abstract] [Full Text] [PDF]

				M. Woodhead, F. Blasi, S. Ewig, G. Huchon, M. Leven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, and T. J. M. Verheij Guidelines for the management of adult lower respiratory tract infections Eur. Respir. J., December 1, 2005; 26(6): 1138 - 1180. [Abstract] [Full Text] [PDF]

				W. MacNee Treatment of stable COPD: antioxidants Eur. Respir. Rev., September 1, 2005; 14(94): 12 - 22. [Abstract] [Full Text] [PDF]

				A.-C. Olofsson, M. Hermansson, and H. Elwing Use of a Quartz Crystal Microbalance To Investigate the Antiadhesive Potential of N-Acetyl-L-Cysteine Appl. Envir. Microbiol., May 1, 2005; 71(5): 2705 - 2712. [Abstract] [Full Text] [PDF]

				M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 343 - 349. [Abstract] [Full Text] [PDF]

				C. Steurer-Stey, L. M. Bachmann, J. Steurer, and M. R. Tramer Oral Purified Bacterial Extracts in Chronic Bronchitis and COPD: Systematic Review Chest, November 1, 2004; 126(5): 1645 - 1655. [Abstract] [Full Text] [PDF]

				K. M. Beeh, J. Beier, N. Koppenhoefer, and R. Buhl Increased Glutathione Disulfide and Nitrosothiols in Sputum Supernatant of Patients With Stable COPD Chest, October 1, 2004; 126(4): 1116 - 1122. [Abstract] [Full Text] [PDF]

				P.N.R. Dekhuijzen Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease Eur. Respir. J., April 1, 2004; 23(4): 629 - 636. [Abstract] [Full Text] [PDF]

				M. Mata, A. Ruiz, M. Cerda, M. Martinez-Losa, J. Cortijo, F. Santangelo, A. Serrano-Mollar, A. Llombart-Bosch, and E.J. Morcillo Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats Eur. Respir. J., December 1, 2003; 22(6): 900 - 905. [Abstract] [Full Text] [PDF]

				A.-C. Olofsson, M. Hermansson, and H. Elwing N-Acetyl-L-Cysteine Affects Growth, Extracellular Polysaccharide Production, and Bacterial Biofilm Formation on Solid Surfaces Appl. Envir. Microbiol., August 1, 2003; 69(8): 4814 - 4822. [Abstract] [Full Text] [PDF]

				S. Burge and J.A. Wedzicha COPD exacerbations: definitions and classifications Eur. Respir. J., June 1, 2003; 21(41_suppl): 46S - 53s. [Abstract] [Full Text] [PDF]

				C.M.J.M. Gerrits, R.M.C. Herings, H.G.M. Leufkens, and J-W.J. Lammers N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease Eur. Respir. J., May 1, 2003; 21(5): 795 - 798. [Abstract] [Full Text] [PDF]

				A. Tietz, M. H Heim, U. Eriksson, S. Marsch, L. Terracciano, and S. Krahenbuhl Fulminant Liver Failure Associated with Clarithromycin Ann. Pharmacother., January 1, 2003; 37(1): 57 - 60. [Abstract] [Full Text] [PDF]

				C. Stey Acute Exacerbations of Chronic Obstructive Pulmonary Disease Ann Intern Med, April 2, 2002; 136(7): 556 - 557. [Full Text] [PDF]

				S. De Flora, A. Izzotti, F. D'Agostini, and R. M. Balansky Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points Carcinogenesis, July 1, 2001; 22(7): 999 - 1013. [Abstract] [Full Text] [PDF]

				M. Decramer, P.N.R. Dekhuijzen, T. Troosters, C. van Herwaarden, M. Rutten-van Molken, C.P.O. van Schayck, D. Olivieri, I. Lankhorst, and A. Ardia The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design Eur. Respir. J., March 1, 2001; 17(3): 329 - 336. [Abstract] [Full Text] [PDF]